Rani Therapeutics Q2 2023 net loss $18.7M; cash $74.6M; expands Celltrion partnership

Rani Therapeutics Holdings, Inc.

2023-Q2 EPS reported $0.70

Net loss of $18.7M for Q2 2023, up from $16.0M in Q2 2022; cash and securities $74.6M (down from $98.5M at YE 2022).
Expanded Celltrion partnership to develop RT-105 (adalimumab biosimilar) using high-capacity RaniPill HC device.
Appointed Kate McKinley as Chief Business Officer, bringing 20 years of biopharma experience.
Plan to initiate Phase 2 for RT-102 and Phase 1 for RT-111 (monoclonal antibody) in H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rani Therapeutics Holdings, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $18.7 million.

Period: second quarter ended June 30, 2023
Net income: Net loss for the three months ended June 30, 2023, was $18.7 million
Result: reported results

Exact text from the filing

On August 11, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.